Stocks fell a sixth day on Monday as weaker-than-expected U.S. manufacturing data and uncertainty over the debt deal in Washington kept the mood skittish on Wall Street.
Merck & Co Inc plans to cut another 12,000 to 13,000 jobs by late 2015 to wring out additional annual cost savings of up to $1.5 billion that can be plowed back into research and deal making.
At least three private equity firms are planning to bid for a clutch of GlaxoSmithKline's non-prescription products, expecting limited competition from rival large pharma groups, people familiar with the process said.
Pharmaceutical giant Pfizer (PFE) is considering selling its animal health and baby food units in hopes of appeasing shareholders' demands.
Researches have found that Chantix, the popular Pfizer drug that helps people quit smoking, may instead give people heart attacks and other cardiovascular problems.
A study showed an increase in the risk of heart attacks and other cardiovascular cases among smokers who take the drug Chantix to help them quit.
Pfizer Inc
may have won over shareholders with its recent decision to pare back research and development spending but could be shortchanging them in the long run, according to its former research chief.A study says Toyota leads global companies in total dollars invested in research and development.
Eli Lilly and Co is committed to spending what it takes to come up with innovative drugs over the long term, its chief executive said, even though the company's earnings are expected to tumble over the next three years.
The top pre-market NASDAQ Stock Market gainers are: Westport Innovations, ICAgen, SIGA Technologies, Spreadtrum Communications, and OmniVision Technologies. The top pre-market NASDAQ Stock Market losers are: Swisher Hygiene, JA Solar Holdings, Logitech International, ASML Holding, and Aixtron.
The top pre-market NASDAQ Stock Market gainers are: Icagen, Pacific Biosciences of California, Sangamo Biosciences, Columbia Laboratories, and Sina. The top pre-market NASDAQ Stock Market losers are: Pain Therapeutics, Logitech International, Zalicus, Partner Communications, and Spreadtrum Communications.
The top pre-market NASDAQ Stock Market gainers are: ASM International, Tibco Software, Comcast, SIRIUS XM Radio, and Sina. The top pre-market NASDAQ Stock Market losers are: Pain Therapeutics, Durect, Micron Technology, Oracle, and Finish Line.
The companies whose shares are moving in pre-market trade on Thursday are: Bristol Myers Squibb, Red Hat, Pfizer, Bed Bath & Beyond, Walgreen, Lennar, Conagra Foods, Nabors Industries, Expedia and Hess Corp.
Stocks rose on Monday, as a move toward a key technical level on the S&P 500 drew support, while the latest plan to help Greece solve its debt woes eased some investor worries.
Stocks advanced on Monday, as the S&P 500 bounced off a key support level and Greece was given an ultimatum by euro-zone ministers in an effort to deal with its debt crisis.
Stocks were little changed on Monday as investors were hesitant to buy riskier assets after a decision was delayed on emergency loans to Greece and Moody's said it may downgrade Italy's credit rating.
The Food and Drug Administration (FDA) said Pfizer's anti-smoking drug called Chantix needs to change its labeling in order to warn patients that using the medicine can slightly increase the risk of heart problems for those who already suffer from cardiovascular disease.
Disappointing trade data from China and the scrapping of a large IPO fed into fears about market volatility and the economy on Friday, with U.S. stocks set to fall a day after rebounding from a six-day losing streak.
Disappointing trade data from China and the scrapping of a large IPO fed into fears about market volatility and the economy on Friday, sending futures lower a day after stocks bounced from a six-day losing streak.
The International Criminal Court's chief prosecutor has accused embattled Libyan leader Moammar Gaddafi of ordering the mass rape of Libyan women.
Pfizer Inc posted disappointing revenue for Lipitor and other medicines, exposing the risks the world's biggest drugmaker faces if it sells better-performing units like its nutritional products business.
Pfizer Inc reported disappointing revenue for Lipitor and other medicines, exposing the risks the world's biggest drugmaker faces if it sells better-performing units like its nutritional products business.
